UroGen Pharma Ltd.URGNNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
0.00%
↓ 100% below average
Average (39q)
3.81%
Historical baseline
Range
High:111.94%
Low:-100.00%
Volatility
5561.0%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 0.00% |
| Q2 2025 | -100.00% |
| Q1 2025 | 33.42% |
| Q4 2024 | 31.17% |
| Q3 2024 | -26.28% |
| Q2 2024 | -0.59% |
| Q1 2024 | 37.09% |
| Q4 2023 | 10.48% |
| Q3 2023 | -11.69% |
| Q2 2023 | -7.31% |
| Q1 2023 | -13.67% |
| Q4 2022 | 10.57% |
| Q3 2022 | 3.58% |
| Q2 2022 | -0.44% |
| Q1 2022 | -2.95% |
| Q4 2021 | 9.72% |
| Q3 2021 | -1.66% |
| Q2 2021 | 15.32% |
| Q1 2021 | -15.25% |
| Q4 2020 | 21.49% |
| Q3 2020 | 25.97% |
| Q2 2020 | -51.13% |
| Q1 2020 | -17.45% |
| Q4 2019 | 111.94% |
| Q3 2019 | -5.15% |
| Q2 2019 | 2.78% |
| Q1 2019 | -15.17% |
| Q4 2018 | 19.75% |
| Q3 2018 | 15.73% |
| Q2 2018 | 8.54% |
| Q1 2018 | 12.73% |
| Q4 2017 | 20.28% |
| Q3 2017 | 53.96% |
| Q2 2017 | 37.05% |
| Q1 2017 | 12.31% |
| Q4 2016 | -17.44% |
| Q3 2016 | 22.20% |
| Q2 2016 | -16.22% |
| Q1 2016 | -61.23% |
| Q4 2015 | 0.00% |